Abstract:Background: Signal transducers and activators of transcription (STAT) family consist of seven structurally similar and highly conserved members, including STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6. The STAT3 signaling cascade is activated by upstream kinase signals and undergoes phosphorylation, homo-dimerization, nuclear translocation, and DNA binding, resulting in the expression of target genes involved in tumor cell proliferation, metastasis, angiogenesis, and immune editing. STAT3 hyperactivation has been documented in a number of tumors, including head and neck, breast, lung, liver, kidney, prostate, pancreas cancer, multiple myeloma, and acute myeloid leukemia. Drug discovery is a time-consuming and costly process, to bring a single drug to the market, may take ten to fifteen years. Machine learning algorithms are very fast as well as effective that are commonly used in the field such as drug discovery. These algorithms are ideal for the virtual screening of large compound libraries to classify molecules as active or inactive. Objective: The present work aims to perform machine learning based virtual screening for STAT3 drug target. Methods: Machine learning models such as k-nearest neighbor, support vector machine, Gaussian naïve Bayes, and random forest for classifying the active and inactive inhibitors against a STAT3 drug target were developed. Ten-fold cross-validation was used for model validation. Then the test dataset prepared from the zinc database was screened using the random forest model. Total of 20 compounds with 88% accuracy was predicted as active against STAT3. Furthermore, these twenty compounds were docked into the active site of STAT3. The two complexes with good docking scores as well as the reference compound were subjected to MD simulation. A total of 100ns MD simulation was performed. Results: Compared to all other models, random forest model revealed better results. Compared to the standard reference compound, the top two hits revealed greater stability and compactness. Conclusion: In conclusion, our predicted hits have the ability to inhibit STAT3 overexpression to combat the STAT3 associated diseases. Keywords: Machine learning, STAT3, Virtual screening, Docking, MD simulation, drug target.

Discovery of novel ULK1 inhibitors through machine learning-guided virtual screening and biological evaluation

Integrating Machine Learning-Based Virtual Screening With Multiple Protein Structures and Bio-Assay Evaluation for Discovery of Novel GSK3β Inhibitors

Integration of Multicomplex‐Based Pharmacophore Modeling and Molecular Docking in Machine Learning‐Based Virtual Screening: Toward the Discovery of Novel PI3K Inhibitors

Identification of novel inhibitors targeting PI3Kα via ensemble-based virtual screening method, biological evaluation and molecular dynamics simulation

Active Learning-Driven Discovery and Dynamics Simulation of Novel SQLE Inhibitors with ADMET Analysis and Molecular Modification

Machine learning accelerates pharmacophore-based virtual screening of MAO inhibitors

Identification of Potent CDK9 Inhibitors with Novel Skeletons Via Virtual Screening, Biological Evaluation, and Molecular Dynamics Simulation

Kinome-Wide Virtual Screening by Multi-Task Deep Learning

Multiple Machine Learning Methods Aided Virtual Screening of NaV 1.5 Inhibitors.

Discovery of novel SOS1 inhibitors using machine learning

Optimization of virtual screening against phosphoinositide 3-kinase delta: Integration of common feature pharmacophore and multicomplex-based molecular docking

Development, validation, and evaluation of a deep learning model to screen cyclin-dependent kinase 12 inhibitors in cancers

Screening, Optimization, and ADMET Evaluation of HCJ007 for Pancreatic Cancer Treatment Through Active Learning and Dynamics Simulation

Machine Learning-Enabled Pipeline for Large-Scale Virtual Drug Screening

Discovery of human autophagy initiation kinase ULK1 inhibitors by multi-directional in silico screening strategies

Machine learning-based virtual screening for STAT3 anticancer drug target.

Establishment of extensive artificial intelligence models for kinase inhibitor prediction: Identification of novel PDGFRB inhibitors

Consensus holistic virtual screening for drug discovery: a novel machine learning model approach

Discovery of novel selective PI3Kγ inhibitors through combining machine learning-based virtual screening with multiple protein structures and bio-evaluation

Feasibility of using molecular docking-based virtual screening for searching dual target kinase inhibitors

Discovery of Novel c-Jun N-Terminal Kinase 1 Inhibitors from Natural Products: Integrating Artificial Intelligence with Structure-Based Virtual Screening and Biological Evaluation